Wednesday 2nd July 2025 |
Text too small? |
On 14 October 2024, based on the information we had on hand at the time, we advised the market about a breach of contract by Bluestone Pharma GmbH (BSP) and Lactosan GmbH & Co. KG (Lactosan).
Since then, BSP and BLIS Technologies Limited (BLIS) have been progressing communications in relation to the patent applications filed by BSP. BLIS and BSP are pleased to report that these negotiations have concluded, with BSP and BLIS agreeing that the patent applications will be jointly owned. This is a positive step forward for both BLIS, BSP and Lactosan, and provides certainty of access for BLIS and its licensees to this market leading technology developed, and contributed to, by BLIS, BSP and Lactosan. As part of this arrangement, BLIS, BSP and Lactosan have released each other of all claims and causes of action arising from the publication of the patent applications.
BLIS would like to thank both BSP and Lactosan for their willingness to engage positively on this matter and the transparent and ethical manner in which both parties have conducted themselves during the course of the negotiations.
BLIS and BSP are also pleased to announce they have renegotiated a five year extension to their existing supply agreement that was scheduled to expire this month.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About BLIS Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.
No comments yet
ikeGPS Chief Financial Officer Transition
TWL - TradeWindow announces strategic partnership with FTA
July 2nd Morning Report
July 1st Morning Report
June 27th Morning Report
SDL - FY2026 Earnings Guidance
PaySauce Director resigns for US-based role with NZTE
General Capital Releases 2025 Annual Report
June 26th Morning Report
Devon Funds Morning Note - 25 June 2025